Trane Technologies’ Thermo King Will Deliver All-Electric, Zero-Emission Solutions for End-to-End Cold Chain by 2023
30.8.2021 13:45:00 EEST | Business Wire | Press release
Thermo King, a brand of global climate innovator Trane Technologies (NYSE: TT), today announced that it will invest more than $100 million over the next three years to deliver a fully electric product in every segment of the cold chain by 2023.
The company’s all-electric portfolio, branded evolve™, will include electric refrigeration solutions for truck, trailer, rail, air and marine transport in the North America, Latin America and Europe, Middle East and Africa (EMEA) regions. The evolve portfolio aligns with customers’ goals to transition to more sustainable solutions for their fleets, and will help advance Trane Technologies’ 2030 Sustainability Commitments, including its Gigaton Challenge to reduce customer greenhouse gas emissions by 1 billion metric tons.
As new products are added to the evolve portfolio, electric solutions will be available in every cold chain segment in EMEA by 2023, and in the Americas by 2025.
“Bold solutions for a more sustainable world are core to our strategy. We continue to innovate to help reduce the carbon footprint of customer operations,” said Paul Camuti, chief technology and sustainability officer for Trane Technologies. “The evolve portfolio builds on our ongoing efforts to help customers reduce environmental impact and meet their sustainability goals as they transition fleets and stay ahead of future regulation.”
The global leader in temperature control solutions already offers fully electric products such as the E-200 for middle and last-mile delivery, and the TE-18 and Athenia™ all-electric HVAC units for public bus transit. Successfully launched in EMEA in 2020, the Advancer trailer unit is 30% more fuel efficient than the market average and can operate on a variety of power sources such as shore power, hybrid, holdover battery and axle generator. In the Americas region, the enhanced electric architecture on the connected Precedent™ trailer unit leverages shore power and will undergo field trials with customers later this year. These innovations will pave the way for all-electric zero-emission trailer refrigeration units in both regions.
“Our expertise in electrification has positioned Thermo King as a trusted partner to respected industry leaders such as Isuzu, Tesco, Mercedes-Benz and technology companies such as ELMS, Gatik and BPW who continue to find new ways to innovate the cold chain,” said Karin De Bondt, president for Thermo King Americas. “Through these strategic partnerships we are able to further our advancements of sustainable power solutions and electrified product offerings that meet customer, regulatory and environmental requirements in our industry and our world.”
Providing electric solutions for buildings, homes and refrigerated transportation is part of Trane Technologies’ overall approach to reducing carbon emissions in the industries it serves, meeting its Gigaton Challenge for a more sustainable future, and supporting net-zero cities.
*The Thermo King evolve™ portfolio will include fully electric products and hybrid products using an internal combustion engine for an emergency backup power source only.
About Thermo King
Thermo King – by Trane Technologies (NYSE: TT), a global climate innovator – is a worldwide leader in sustainable transport temperature control solutions. Thermo King has been providing transport temperature control solutions for a variety of applications, including trailers, truck bodies, buses, air, shipboard containers, and railway cars since 1938. For more information, visit www.thermoking.com or www.europe.thermoking.com.
About Trane Technologies
Trane Technologies is a global climate innovator. Through our strategic brands Trane and Thermo King, and our environmentally responsible portfolio of products and services, we bring efficient and sustainable climate solutions to buildings, homes, and transportation. Learn more at tranetechologies.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005123/en/
Contact information
Media:
Jennifer Regina, Trane Technologies
+1-630-390-8011
jennifer.regina@tranetechnologies.com
Investors:
Zachary Nagle, Trane Technologies
+1-704-990-3913
zachary.nagle@tranetechnologies.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 13:17:00 EEST | Press release
Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 12:11:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechnology executive, bringing over two decades of therapeutic and diagnostic R&D experience within industry to Mosaic Therapeutics, with a track record spanning from IND through to NDA/BLA/MAA approval. Most recently he served at BioXcel Therapeutics as EVP, Head of Product Developme
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 10:00:00 EEST | Press release
The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights - equipping executives with the perspective needed to make confident, high-stakes decisions. “Through our work we increasingly s
Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 09:00:00 EEST | Press release
As millions of Europeans2 get ready to enjoy the Easter weekend, new research from Samsung finds Europe’s public spaces have become shared screens: 56% of people say they have accidentally looked at a stranger’s phone, citing public transport as the most likely place to notice someone else’s screen (57%). Nearly one in four Europeans2 (24%) admit to looking at someone else’s phone out of curiosity, exposing a stream of private content from personal photos to bank details. Samsung Electronics surveyed 11,000 Europeans2 to support the launch of the Galaxy S26 Ultra, which introduces a built-in Privacy Display. This new hardware-based technology keeps screen content visible only from the front to protect privacy from side angles, without compromising the viewing experience3. The study further reveals a gap between perceived phone privacy and reality: While 48%* feel their own phone use is private when using it in crowded places, 52%** find it easy to view someone else’s screen in public.
RevolKa Reimagines Antibody Engineering with "RevoAb ® "1.4.2026 07:30:00 EEST | Press release
RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allows researchers worldwide to experience RevolKa’s high-performance antibody design. Key Advantages of RevoAb® Speed: Multiple optimi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom